Approach to recurrent hepatitis C following liver transplantation

Current Gastroenterology Reports

Volumn 9, Issue 1, 2007, Pages 23-30

  Charlton, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BILIRUBIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; HEPATITIS ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; PLACEBO; RAPAMYCIN; RIBAVIRIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANEMIA; ANTIVIRAL ACTIVITY; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG WITHDRAWAL; FATALITY; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION; INFECTION RISK; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MORTALITY; NONHUMAN; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; RECURRENT INFECTION; REINFECTION; RETRANSPLANTATION; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; T CELL DEPLETION; TREATMENT INDICATION; VIREMIA;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS C; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS; VIREMIA;

EID: 33947649539     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0017-8     Document Type: Review

References (72)

1. Charlton M, Seaberg E, Wiesner R, et al.: Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28:823-830.
2. Negro F, Krawczynski K, Quadri R, et al.: Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. Hepatology 1999, 29:536-542.
3. Negro F, Giostra E, Krawczynski K, et al.: Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model. J Hepatol 1998, 29:1-11.
4. Garcia-Retortillo M, Forns X, Feliu A, et al.: Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002, 35:680-687.
5. Gretch DR, Bacchi CE, Corey L, et al.: Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995, 22:1-9.
6. Papatheodoridis GV, Barton SG, Andrew D, et al.: Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens [see comments]. Gut 1999,45:427-434.
7. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al.: Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000, 32:1125-1130.
8. Gane EJ, Naoumov NV, Qian KP, et al.: A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996, 110:167-177.
9. Calleja JL, Albillos A, Cacho G, et al.: Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol 1996, 24:308-312.
10. Fong TL, Valinluck B, Govindarajan S, et al.: Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994, 107:196-199.
11. Schoeman MN, Liddle C, Bilous M, et al.: Chronic non-A, non-B hepatitis: lack of correlation between biochemical and morphological activity, and effects of immunosuppressive therapy on disease progression. Austr N Z J Med 1990, 20:56-62.
12. Ahlman B, Charlton M, Fu A, et al.: Insulin's effect on synthesis rates of liver proteins: A swine model comparing various precursors of protein synthesis. Diabetes 2001, 50:947-954.
13. Charlton M, Seaberg E: Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999, 5(Suppl 1):107-114.
14. Firpi RJ, Zhu H, Morelli G, et al.: Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation [see comment]. Liver Transpl 2006, 12:51-57.
15. Martin P, Busuttil RW, Goldstein RM, et al.: Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004, 10:1258-1262.
16. Kakumu S, Takayanagi M, Iwata K, et al.: Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. J Gastroenterol Hepatol 1997, 12:62-66.
17. Zervos XA, Weppler D, Fragulidis GP, et al.: Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998, 65:1044-1046.
18. Gane EJ, Portmann BC, Naoumov NV, et al.: Long-term outcome of hepatitis C infection after liver transplantation [see comments]. N Engl J Med 1996, 334:815-820.
19. Berenguer M, Aguilera V, Prieto M, et al.: Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients [see comment]. Liver Transpl 2006, 12:762-767.
20. Firpi RJ, Nelson DR, Davis GL: Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transpl 2003, 9:57-61.
21. Berenguer M, Watson J, Crippin JS, et al.: A model to predict HCV-related fibrosis progression following liver transplantation [abstract]. Hepatology 2001, 32:217A.
22. Wiesner RH, Rabkin J, Klintmalm G, et al.: A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001, 7:442-450.
23. Jain A, Kashyap R, Demetris AJ, et al.: A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C [comment]. Liver Transpl 2002, 8:40-46.
24. Wiesner RH, Shorr JS, Steffen BJ, et al.: Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005, 11:750-759.
25. Rosen HR, Shackleton CR, Higa L, et al.: Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation [see comments]. Am J Gastroenterol 1997, 92:1453-1457.
26. Sheiner PA, Schwartz ME, Mor E, et al.: Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995, 21:30-34.
27. Nelson DR, Soldevila-Pico C, et al.: Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001, 7:1064-1070.
28. Jain S, Bicknell GR, Whiting PH, Nicholson ML: Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury. Transplant Proc 2001, 33:556-558.
29. Guerrero RB, Batts KP, Burgart LJ, et al.: Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000, 13:229-237.
30. Feray C, Caccamo L, Alexander GJ, et al.: European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999, 117:619-625.
31. Berenguer M, Ferrell L, Watson J, et al.: HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000, 32:673-684.
32. Schluger LK, Sheiner PA, Thung SN, et al.: Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996, 23:971-976.
33. Lim HL, Lau GK, Davis GL, et al.: Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology 1994, 106:248-251.
34. Dickson RC, Caldwell SH, Ishitani MB, et al.: Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996, 61:701-705.
35. Charlton M, Ruppert K, Belle SH, et al.: Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004, 10:1120-1130.
36. Forman LM, Lewis JD, Berlin JA, et al.: The association between hepatitis C infection and survival after orthotopic liver transplantation [see comments]. Gastroenterology 2002, 122:889-896.
37. Gordon FD, Poterucha JJ, Germer J, et al.: Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997, 63:1419-1423.
38. Vargas HE, Laskus T, Wang LF, et al.: The influence of hepatitis C virus genotypes on the outcome of liver transplantation [see comments]. Liver Transpl Surg 1998, 4:22-27.
39. Sanchez-Fueyo A, Gimenez-Barcons M, Puig-Basagoiti F, et al.: Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J Med Virol 2001, 65:266-275.
40. Sullivan DG, Wilson JJ, Carithers RLJ, et al.: Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns. J Virol 1998, 72:10036-10043.
41. Hayashi J, Furusyo N, Ariyama I, et al.: A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. J Infect Dis 2000, 181:1523-1527.
42. Cotler SJ, Gaur LK, Gretch DR, et al.: Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Tissue Antigens 1998, 52:435-443.
43. Prieto M, Nicolas D, Rayon JM, et al.: Donor-recipient HLA matching does not predict accelerated progression of hepatitis C following liver transplantation in genotype 1b patients [abstract]. Hepatology 2000, 32:261A.
44. Berenguer M, Prieto M, San Juan F, et al.: Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002, 36:202-210.
45. Burak KW, Kremers WK, Batts KP, et al.: Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002, 8:362-369.
46. Wali M, Harrison RF, Gow PJ, Mutimer D: Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002, 51:248-252.
47. Baron PW, Sindram D, Higdon D, et al.: Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. [see comments.]. Liver Transpl 2000, 6:407-412.
48. Taniguchi M, Wachs M, Bak T, Trotter J: Hepatitis C recurrence in living donor liver transplantation [abstract]. Am J Transpl 2002, 2:138.
49. Ghobrial RM, Amherst F, Farmer DG, et al.: Rapid and severe early HCV recurrence following adult living donor liver transplantation [abstract]. Am J Transpl 2002, 2:163.
50. Rosen HR, Chou S, Corless CL, et al.: Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997, 64:721-726.
51. Crippin JS, McCashland TM, Terrault NA, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation [abstract]. Liver Transpl 2002, 8:350-355.
52. Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
53. Chalasani N, Manzarbeitia C, Ferenci P, et al.: Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.[see comment]. Hepatology 2005, 41:289-298.
54. Castells L, Vargas V, Allende H, et al.: Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005, 43:53-59.
55. Neumann U, Puhl G, Bahra M, et al.: Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006, 82:43-47.
56. Vargas HE, Rosati MJ, Douglas DD, et al.: Combination pegylated interferon alpha-2b and ribavirin in transplant patients with recurrent hepatitis C infection: A preliminary report [abstract). Hepatology 2001, 34:407A.
57. Feray C, Samuel D, Gigou M, et al.: An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995, 22:1084-1089.
58. Kapur A, Rodriguez MJ, Schecter P, et al.: Interferon alfa and ribavirin in established post liver transplant recurrent hepatitis C infection [abstract]. Gastroenterology 1998, 114:A1268.
59. Willner IR, Chavin KD, Rogers J, et al.: Combination interferon-ribavirin is ineffective and poorly tolerated by liver transplant recipients with genotype 1 recurrent hepatitis C [abstract]. Hepatology 2000, 32:290A.
60. Menon KVN, Poterucha JJ, El-Amin OA, et al.: Treatment of posttransplant recurrence of hepatitis C infection with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002, 8:623-629.
61. Lavezzo B, Franchello A, Smedile A, et al.: Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin[comment]. J Hepatol 2002, 37:247-252.
62. Samuel D, Bizollon T, Feray C, et al.: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642-650.
63. Feray C, Gigou M, Samuel D, et al.: Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998, 128:810-816.
64. Willems B, Ede M, Marotta P, et al.: Anti-HCV human immunoglobulin for the prevention of graft infection in HCV-related liver transplantation: a pilot study [abstract]. J Hepatol 2002, 36:32.
65. Davis GL, Nelson DR, Terrault N, et al.: A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Transplantation 1997, 64:422-426.
66. Belli LS, Zavaglia C, Alberti AB, et al.: Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation. Hepatology 2000, 31:1345-1350.
67. Feray C, Gigou M, Samuel D, et al.: Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation [see comments]. Gastroenterology 1995, 108:1088-1096.
68. Belli LS, Silini E, Alberti A, Bellati G, Vai C, Minola E, et al.: Hepatitis C virus genotypes, hepatitis, and hepatitis C virus recurrence after liver transplantation. Liver Transpl Surg 1996, 2:200-205.
69. Gayowski T, Singh N, Marino I, et al.: Hepatitis C virus genotypes in liver transplant recipients. Transplantation 1997, 64:422-426.
70. Ghobrial RM, Farmer DG, Baquerizo A, et al.: Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999, 229:824-831.
71. Doughty AL, Spencer JD, Cossart YE, McCaughan GW: Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998, 4:15-21.
72. Razonable RR, Burak KW, van Cruijsen H, et al.: The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002, 35:974-981.